country

Change Language

EN - English
FR - Français
DE - Deutsch
ES - Español
JA - 日本語
KO - 한국어

Country or Region:

United States

Product Name	Size / Unit Price	Qty

Total: USD 0.00 Checkout

Art. -Nr.: HY-14135

Copy Link Print Information

BMS 488043

(Synonyms: BMS 043)

BMS 488043 (BMS 043) is an orally active and well-tolerated inhibitor of the attachment of human immunodeficiency virus type 1 (HIV-1) to CD4+ lymphocytes.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 452296-83-2
Formel: C₂₂H₂₂N₄O₅
Molecular Weight:422.43

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (271 KB)

BMS 488043 Chemical Structure

CAS. Nr.: 452296-83-2

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

BMS 488043 (BMS 043) is an orally active and well-tolerated inhibitor of the attachment of human immunodeficiency virus type 1 (HIV-1) to CD4+ lymphocytes^[1].

Alle HIV Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
Cancer cell lines	CC₅₀	>=120 μM Compound: 4, BMS-488043	Cytotoxicity against human cervical cancer cells Cytotoxicity against human cervical cancer cells	[PMID: 19769332]
Cancer cell lines	CC₅₀	>=120 μM Compound: 4, BMS-488043	Cytotoxicity against human hepatic cancer cells Cytotoxicity against human hepatic cancer cells	[PMID: 19769332]
Cancer cell lines	CC₅₀	>=120 μM Compound: 4, BMS-488043	Cytotoxicity against human larynx cancer cells Cytotoxicity against human larynx cancer cells	[PMID: 19769332]
Cancer cell lines	CC₅₀	>=120 μM Compound: 4, BMS-488043	Cytotoxicity against human lung cancer cell Cytotoxicity against human lung cancer cell	[PMID: 19769332]
HEK293	CC₅₀	>=120 μM Compound: 4, BMS-488043	Cytotoxicity against HEK cells Cytotoxicity against HEK cells	[PMID: 19769332]
HeLa	CC₅₀	>300 μM Compound: 2, BMS-488043	Cytotoxicity against human HeLa cells expressing CD4 assessed as cell viability after 6 days by XTT assay Cytotoxicity against human HeLa cells expressing CD4 assessed as cell viability after 6 days by XTT assay	[PMID: 23200252]
HeLa	EC₅₀	0.75 nM Compound: 2, BMS-488043	Antiviral activity against HIV1 JRFL infected in human HeLa cells expressing CD4 and CCR5 assessed as inhibition of single-cycle viral replication by luciferase reporter gene assay Antiviral activity against HIV1 JRFL infected in human HeLa cells expressing CD4 and CCR5 assessed as inhibition of single-cycle viral replication by luciferase reporter gene assay	[PMID: 23200252]
HeLa	CC₅₀	248 μM Compound: 1, BMS-488043	Cytotoxicity against human HeLa cells Cytotoxicity against human HeLa cells	[PMID: 23360431]
MT2	CC₅₀	>300 μM Compound: 4, BMS-488043	Cytotoxicity against human MT2 cells after 3 days by XTT assay Cytotoxicity against human MT2 cells after 3 days by XTT assay	[PMID: 19769332]
MT2	EC₅₀	3.44 nM Compound: 1, BMS-488043	Antiviral activity against X4-tropic HIV1 LAI infected in MT2 cells Antiviral activity against X4-tropic HIV1 LAI infected in MT2 cells	[PMID: 23360431]
MT2	EC₅₀	5.58 nM Compound: 1, BMS-488043	Antiviral activity against X4-tropic HIV1 NL4-3 infected in MT2 cells Antiviral activity against X4-tropic HIV1 NL4-3 infected in MT2 cells	[PMID: 23360431]
MT2	EC₅₀	8.32 nM Compound: 1, BMS-488043	Antiviral activity against X4-tropic HIV1 MN infected in MT2 cells Antiviral activity against X4-tropic HIV1 MN infected in MT2 cells	[PMID: 23360431]
MT2	CC₅₀	>300 μM Compound: 2; BMS-488043	Cytotoxicity against human MT2 cells assessed as decrease in cell viability after 3 days by XTT assay Cytotoxicity against human MT2 cells assessed as decrease in cell viability after 3 days by XTT assay	[PMID: 29920093]
PBMC	CC₅₀	>=120 μM Compound: 4, BMS-488043	Cytotoxicity against human PBMC Cytotoxicity against human PBMC	[PMID: 19769332]
T-cell	CC₅₀	>=120 μM Compound: 4, BMS-488043	Cytotoxicity against human T cell Cytotoxicity against human T cell	[PMID: 19769332]
U-87MG ATCC	IC₅₀	26 nM Compound: 27, BMS-488043	Antiviral activity against HIV1 pseudovirus in U87 cells expressing CD4 and CCR5 after 72 hrs by M33 pseudotyped assay Antiviral activity against HIV1 pseudovirus in U87 cells expressing CD4 and CCR5 after 72 hrs by M33 pseudotyped assay	[PMID: 18052117]
U-87MG ATCC	CC₅₀	>40000 nM Compound: 27, BMS-488043	Cytotoxicity against human U87 cells expressing CD4 and CXCR4 Cytotoxicity against human U87 cells expressing CD4 and CXCR4	[PMID: 18052117]
U-87MG ATCC	CC₅₀	>40000 nM Compound: 2, BMS-488043,BMS-043	Cytotoxicity against human U87 cells coexpressing CD4, CxCR4 receptors after 72 hrs Cytotoxicity against human U87 cells coexpressing CD4, CxCR4 receptors after 72 hrs	[PMID: 19534463]

Chemical Information

CAS. Nr. 452296-83-2
Molecular Weight 422.43
Formel C₂₂H₂₂N₄O₅
SMILES

O=C(C1=CNC2=C1C(OC)=CN=C2OC)C(N3CCN(CC3)C(C4=CC=CC=C4)=O)=O
Synonyms

BMS 043
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (271 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. George J Hanna, et al. Antiviral activity, pharmacokinetics, and safety of BMS-488043, a novel oral small-molecule HIV-1 attachment inhibitor, in HIV-1-infected subjects. Antimicrob Agents Chemother. 2011 Feb;55(2):722-8. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

MOQ

Minimum order quantity

100 mg

Angebot einholen Auf Lager

Other size

Angebot einholen

Amount: USD 0.00

Biologische Aktivität
- Beschreibung
Chemical Information
Reinheit & Dokumentation
Verweise

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

BMS 488043

Alle HIV Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Reinheit & Dokumentation

Verweise

Calculators

Help & FAQs

BMS 488043 Related Classifications

HY-14135 Related Classifications